dc.contributor
Institut Català de la Salut
dc.contributor
[Bosch C] Instituto Universitario CEMIC, Buenos Aires, Argentina. [Carriazo S] Department of Nephrology and Hypertension, IIS-Fundacion Jimenez Diaz UAM, Madrid, Spain. RICORS2040, Madrid, Spain. [Soler MJ] RICORS2040, Madrid, Spain. Servei de Nefrologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Geendiab (Diabetic Nephropathy working group of the Spanish Society of Nephrology, Sociedad Española de Nefrologia). [Ortiz A] Department of Nephrology and Hypertension, IIS-Fundacion Jimenez Diaz UAM, Madrid, Spain. RICORS2040, Madrid, Spain. Departamento de Medicina, Facultad de Medicina, Universidad Autónoma de Madrid, Madrid, Spain. [Fernandez-Fernandez B] Department of Nephrology and Hypertension, IIS-Fundacion Jimenez Diaz UAM, Madrid, Spain. RICORS2040, Madrid, Spain. Geendiab (Diabetic Nephropathy working group of the Spanish Society of Nephrology, Sociedad Española de Nefrologia). Departamento de Medicina, Facultad de Medicina, Universidad Autónoma de Madrid, Madrid, Spain
dc.contributor
Vall d'Hebron Barcelona Hospital Campus
dc.contributor.author
Bosch, Catalina
dc.contributor.author
Carriazo Julio, Sol Maria
dc.contributor.author
Ortiz Arduan, Alberto
dc.contributor.author
Soler, María José
dc.contributor.author
Fernandez-Fernandez, Beatriz
dc.date.issued
2023-05-15T08:38:22Z
dc.date.issued
2023-05-15T08:38:22Z
dc.identifier
Bosch C, Carriazo S, Soler MJ, Ortiz A, Fernandez-Fernandez B. Tirzepatide and prevention of chronic kidney disease. Clin Kidney J. 2023 May;16(5):797–808.
dc.identifier
https://hdl.handle.net/11351/9529
dc.identifier
10.1093/ckj/sfac274
dc.identifier
000940502300001
dc.description.abstract
Chronic kidney disease; Diabetes mellitus; Obesity
dc.description.abstract
Malaltia renal crònica; Diabetis mellitus; Obesitat
dc.description.abstract
Enfermedad renal crónica; Diabetes mellitus; Obesidad
dc.description.abstract
Tirzepatide is a twincretin recently approved to improve glycemic control in type 2 diabetes mellitus (T2DM). More specifically, tirzepatide is an agonist of both the glucose-dependent insulinotropic polypeptide (GIP) and the glucagon-like peptide-1 (GLP1) receptors. In recent clinical trials in persons with obesity or overweight with associated conditions, tirzepatide decreased body weight and other cardiorenal risk factors (blood pressure, low-density lipoprotein cholesterol, glycated hemoglobin and albuminuria). Moreover, in a post hoc analysis of the SURPASS-4 randomized clinical trial, tirzepatide decreased albuminuria and total estimated glomerular filtration rate (eGFR) slopes and nearly halved the risk of a pre-specified composite kidney endpoint (eGFR decline ≥40%, renal death, kidney failure or new-onset macroalbuminuria) in participants with T2DM and high cardiovascular risk when compared with insulin glargine. Similar to other kidney-protective drugs, tirzepatide, alone or combined with sodium-glucose co-transporter 2 inhibitors, caused an early dip in eGFR. Moreover, tirzepatide also decreased eGFR slopes in participants with eGFR >60 mL/min/1.73 m2 or with normoalbuminuria. We now review the potential kidney health implications of tirzepatide, addressing its structure and function, relationship to current GLP1 receptor agonists, impact of recent results for the treatment and prevention of kidney disease, and expectations for the future.
dc.description.abstract
FIS/Fondos FEDER (PI18/01366, PI19/00588, PI19/00815, PI20/00744, DTS18/00032, ERA-PerMed-JTC2018 KIDNEY AT390 TACK AC18/00064 and PERSTIGAN AC18/00071, ISCIII-RETIC REDinREN RD016/0009), Sociedad Española de Nefrología, Sociedad Madrileña de Nefrología (SOMANE), FRIAT, Comunidad de Madrid en Biomedicina (B2017/BMD-3686 and CIFRA2-CM). Instituto de Salud Carlos III (ISCIII) RICORS program (RICORS2040-395 , RD21/0005/0001) and SPACKDc PMP21/00109, FEDER funds funded by European Union—Next Generation EU’, Mecanismo para la Recuperación y la Resiliencia (MRR) and RD16/0009.
dc.format
application/pdf
dc.publisher
Oxford University Press
dc.relation
Clinical Kidney Journal;16(5)
dc.relation
https://doi.org/10.1093/ckj/sfac274
dc.rights
Attribution-NonCommercial 4.0 International
dc.rights
http://creativecommons.org/licenses/by-nc/4.0/
dc.rights
info:eu-repo/semantics/openAccess
dc.subject
Diabetis no-insulinodependent - Tractament
dc.subject
Ronyons - Malalties - Prevenció
dc.subject
DISEASES::Nutritional and Metabolic Diseases::Metabolic Diseases::Glucose Metabolism Disorders::Diabetes Mellitus::Diabetes Mellitus, Type 2
dc.subject
Other subheadings::Other subheadings::Other subheadings::/drug therapy
dc.subject
DISEASES::Male Urogenital Diseases::Urologic Diseases::Kidney Diseases
dc.subject
Other subheadings::Other subheadings::Other subheadings::/prevention & control
dc.subject
CHEMICALS AND DRUGS::Chemical Actions and Uses::Pharmacologic Actions::Physiological Effects of Drugs::Hypoglycemic Agents
dc.subject
ENFERMEDADES::enfermedades nutricionales y metabólicas::enfermedades metabólicas::trastornos del metabolismo de la glucosa::diabetes mellitus::diabetes mellitus tipo II
dc.subject
Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia
dc.subject
ENFERMEDADES::enfermedades urogenitales masculinas::enfermedades urológicas::enfermedades renales
dc.subject
Otros calificadores::Otros calificadores::Otros calificadores::/prevención & control
dc.subject
COMPUESTOS QUÍMICOS Y DROGAS::acciones y usos químicos::acciones farmacológicas::efectos fisiológicos de los fármacos::hipoglicemiantes
dc.title
Tirzepatide and prevention of chronic kidney disease
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/publishedVersion
